Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
18 10월 2023 - 8:30PM
Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the
“Company”), a clinical-stage biopharmaceutical company leveraging
its extensive virology expertise to develop novel therapeutics that
target specific viral diseases, today announced that the Arbutus
management team will participate in and host one-on-one meetings at
the following investor conference:
H.C. Wainwright 4th Annual Hepatitis B
Virus (HBV) Virtual Conference: Formal Presentation on
October 25, 2023 at 4:30 pm ET
To access the live webcast of the presentation
please visit:
https://investor.arbutusbio.com/events-presentations. An
archived replay of the webcast will be available on the Arbutus
website for a limited time after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to identify and develop novel therapeutics with
distinct mechanisms of action, which can be combined to provide a
functional cure for patients with chronic hepatitis B virus (cHBV).
We believe the key to success in developing a functional cure
involves suppressing HBV DNA, reducing surface antigen, and
boosting HBV-specific immune responses. Our pipeline of internally
developed, proprietary compounds includes an RNAi therapeutic,
imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran
is the only RNAi that has generated meaningful clinical data
demonstrating an impact on both surface antigen reduction and
reawakening of the HBV-specific immune response. Imdusiran is
currently in two Phase 2a combination clinical trials. AB-101 is
currently being evaluated in a Phase 1a/1b clinical trial. We are
also exploring oncology applications for our internal PD-L1
portfolio. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. CaperelliVice President, Investor RelationsPhone:
215-206-1822Email: lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Arbutus Biopharma (NASDAQ:ABUS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024